Presently, the only approved products for treating interstitial cystitis / bladder pain syndrome (IC/BPS) in the US and Europe, are based on clinical studies which have shown the drugs to be marginally effective. Consequently, there remains a significant need for new therapeutic interventions such as URG101 that can address the underlying disease process while also providing acute symptom relief.                        



---